Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ENTR-601-45 · 1 trial · 1 indication
Safety will be assessed by monitoring adverse events, physical examination, vital signs and clinical laboratory tests.
| Arm | Type | Description |
|---|---|---|
| ENTR-601-45 | EXPERIMENTAL | intravenous infusion every 6 weeks |
| Placebo | PLACEBO_COMPARATOR | intravenous infusion every 6 weeks |
| Name | Type | Description |
|---|---|---|
| ENTR-601-45 | DRUG | intravenous infusion |
| ENTR-601-45 - matching placebo | DRUG | intravenous infusion |
Inclusion Criteria: 1. Genetic diagnosis of DMD and confirmed pathologic variant in the dystrophin gene amenable to exon 45 skipping as reviewed by a central genetic counselor. 2. Assigned male at birth with clinical signs compatible with Duchenne muscular dystrophy as determined by the investigato...
ENTR-601-45 is an investigational small molecule developed by Entrada Therapeutics for Duchenne Muscular Dystrophy (DMD). It is designed for patients whose disease is amenable to exon 45 skipping. It is currently in Phase 1 clinical development and has not been approved by the FDA.
ENTR-601-45 is being developed for Duchenne Muscular Dystrophy (DMD) in patients whose mutations make them amenable to exon 45 skipping. It is an investigational therapy in Phase 1 testing and is not yet approved for any indication.
ENTR-601-45 targets DMD exon 45. By directing exon 45 skipping, the small molecule aims to address the underlying genetic cause of Duchenne Muscular Dystrophy in patients with mutations amenable to this approach. It is an investigational agent in Phase 1 development.
ENTR-601-45 is being developed by Entrada Therapeutics, Inc., which trades on the Nasdaq under the ticker TRDA. The company is advancing the small molecule for Duchenne Muscular Dystrophy in patients amenable to exon 45 skipping.
ENTR-601-45 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The Phase 1 study is currently recruiting participants with Duchenne Muscular Dystrophy who are amenable to exon 45 skipping.
ENTR-601-45 is being evaluated in one active clinical trial, NCT07038824, a Phase 1 study in participants with Duchenne Muscular Dystrophy amenable to exon 45 skipping. The trial is recruiting 24 male participants aged 4 years and older across Belgium, Italy, the Netherlands, Spain, and the United Kingdom.